The University of Cincinnati Cancer Center Pilot Project Award Program is dedicated to advancing cancer research by providing pilot funding to our faculty investigators. This Spring 2024 cycle we celebrate 8 investigators whose pilot research received funding.
Full story About: Spring Pilot Project Awardees - May 2024Tammy Mentzel, MPH, has been named Executive Director for Center Administration and Associate Director for Administration at the University of Cincinnati Cancer Center.
Full story About: Tammy Mentzel, MPH Named Executive Director for Center AdministrationAndrew Waters, PhD, a basic scientist at the University of Cincinnati Cancer Center and assistant professor within the Division of Surgical Oncology and the Department of Cancer Biology at UC, runs a research lab focusing on the molecular consequences and resistance mechanisms to KRAS inhibitors.
Full story About: A Spotlight on Pancreatic Cancer at the Waters LaboratoryThe University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to study the efficacy of LN-145 on patients with advanced lung cancer. This treatment involves the infusion of patients’ own immune cells, tumor-infiltrating lymphocytes (TIL), to evaluate the efficacy of LN-145 as determined by objective response rates (ORR).
Full story About: Clinical Trial Highlight: Phase 2 Study Evaluates LN-145 in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)How will the explosion of AI impact cancer research and care? Last month, the University of Cincinnati Cancer Center held the tenth annual Charge Against Cancer Symposium on “Leveraging Artificial Intelligence and Data Sciences to Conquer Cancer” to tackle this topic.
Full story About: 10th Annual Charge Against Cancer Symposium Tackles AIThe University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to compare a lower-than-standard dosage of a widely used treatment in newly diagnosed acute myeloid leukemia (AML) patients. This clinical trial is designed to evaluate the efficacy this dosage and treatment schedule of Venetoclax plus Azacitidine may have for newly diagnosed AML patients.
Full story About: Clinical Trial Highlight: New Beat AML Sub-Study Examines the Efficacy of Using a Lower-Dose of Common Treatment in Patients with Newly Diagnosed AMLFull story About: Clinical Trial Highlight: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma (Imvax 14379-201)
Contact Us
University of CincinnatiCancer Center
231 Albert Sabin Way, Suite 2005
Cincinnati, OH 45267
Phone: 513-558-2177
Fax: 513-558-2666